Beyfortus January 8, 2024 On July 18th, 2023, the FDA approved Beyfortus (nirsevimab-alip) for the prevention of Respiratory Syncytial Virus (RSV) in neonates and infants born during or entering their first RSV season, and in children up Read More
Compounding Pharmacies vs. Big Pharma: The Battle for Dominance in the Growing GLP-1 Market October 22, 2024
